Monoclonal Antibody

Overview

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

B-Cell Maturation Antigen (BCMA)

B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.

CD38

CD38 is a protein that may be found on the surface of many immune system cells (including multiple myeloma cells). This protein may be used as a way for treatments to target (or find) myeloma cells.

Programmed Death Receptor-1 (PD-1)

PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.

Resources

There are no resources, links or videos to display for this tag.